Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Comment by Gbathaton Nov 29, 2021 5:51pm
109 Views
Post# 34177704

RE:For those trying to figure out the status of Serology Test

RE:For those trying to figure out the status of Serology TestNot the most flattering article, by any means, but at least it is something!  

Dr. Eileen Chin seems to know how to get the press to provide free marketing.  

Looks like the governments do not want people deciding when to get boosted... despite continuously flailing and changing guidance over the last two years.  Heaven forbid we get some quantitative indicator of immunity that empowers people to decide for themselves.

It will be interesting to see the omicron progression.  The frenzy is interesting.  My gut says the vaccines probably need to be updated/upgraded anyways to improve their sustained efficacy, and omicron might be a more politically viable cover, rather than just saying the first generation did not work as well as we'd hoped.

NY state actually put out some data showing their stats on breakthrough cases... it is an impressive site.  https://coronavirus.health.ny.gov/covid-19-breakthrough-data   the claim based on the data is a 6-fold reduction in infection risk and sustained reduction in risk of hospitilization.

I think the fact that people who are vaccinated can still be infected creates huge selective pressure for mutants that can evade the immune response.  We are in for a long and arduous journey.  
<< Previous
Bullboard Posts
Next >>